Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD1)…
Phase 3 study failed to meet one of the success criteria of the primary objectiveRSV program to be discontinuedCOPENHAGEN, Denmark,…
MELVILLE, NY / ACCESSWIRE / July 21, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative"), a clinical-stage company specializing in stem…
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in…
Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder valueBOULDER, Colo., July 21, 2023 (GLOBE NEWSWIRE)…
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in…
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary…
The study verified the ability for Triastek's 3D Microstructure for Colon Targeting (3DμS-CT) to precisely target and release medication in…
PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the…
Press release Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to…